|
Glioblastoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Loss of heterozygosity (LOH) on chromosome 10 (LOH#10) is the most frequent genetic alteration in glioblastomas; the involvement of tumor suppressor genes, other than PTEN, has been suggested.
|
10653004 |
2000 |
|
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Restoration of wild-type PTEN to glioblastoma cell lines lacking functional PTEN ablates hypoxia and IGF-1 induction of HIF-1-regulated genes.
|
10691731 |
2000 |
|
Glioblastoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
These findings indicate that the genetic or epigenentic inactivation of the hMLH1 gene is involved in a subset of early-onset gliomas and the PTEN1 gene could be a downstream target for mutation as observed in glioblastoma without MSI.
|
10734316 |
2000 |
|
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Finally we found that SHIP-2, like PTEN, caused a potent cell cycle arrest in G(1) in glioblastoma cells, which is associated with an increase in the stability of expression of the cell cycle inhibitor p27(KIP1).
|
10958682 |
2000 |
|
Glioblastoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
PTEN mutations have been implicated in the development of a variety of human neoplasia, including high-grade glioblastoma, prostate, breast, endometrial, and thyroid carcinoma.
|
10910075 |
2000 |
|
Glioblastoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The lower frequency of PTEN mutations in +7/-10 HG-OT compared to GBM suggests that these tumors are of a distinct tumor type rather than GBM.Published by Elsevier Science Inc.
|
10812170 |
2000 |
|
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
We previously demonstrated that MMAC1/PTEN has tumor suppressive properties in glioblastoma and prostate cancer.
|
11103942 |
2000 |
|
Glioblastoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Mutation of PTEN, amplification of EGFR, and loss of the q arm of chromosome 10 were statistically significantly less common in anaplastic astrocytoma than in glioblastoma multiforme (P =.033, P =.001, and P<.001, respectively), and mutation of p53 was statistically significantly more common (P<.001).
|
11504770 |
2001 |
|
Glioblastoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
All but 4 tumors (84%) showed alterations known to be preferentially involved in the progression of astrocytic tumors to GBM, such as EGFR amplification (44%), P16 deletion (48%), LOH on 10q (64%), PTEN (20%), and TP53 (24%) mutations.
|
11556543 |
2001 |
|
Glioblastoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Excessive activity of the epidermal growth factor receptor and loss of the phosphatase PTEN are associated with glioblastoma, and both genes are required for normal growth and development.
|
11283316 |
2001 |
|
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The LOH on markers D10S215 and D10S541, which contain the PTEN/MMAC1 gene between them, was significantly associated with shorter survival in patients with GBM.
|
11596960 |
2001 |
|
Glioblastoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Unusual findings include: TP53 mutation in a juvenile pilocytic astrocytoma; TP53 and PTEN mutations in a de novo glioblastoma, a gliosarcoma with identical mutations in gliomatous and sarcomatous components, and an infratentorial anaplastic astrocytoma with an earlier supratentorial grade II astrocytoma bearing the same TP53 mutation but not the PTEN mutation or loss of heterozygosity (LOH) of 10q23.
|
11355303 |
2001 |
|
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Interestingly, PTEN effects were mimicked by N-cadherin-neutralizing antibody in the glioblastoma cell lines.
|
11756467 |
2001 |
|
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
PTEN has also been found to be somatically deleted, mutated, and/or silenced in various sporadically occurring cancers such as glioblastoma, breast cancer, kidney cancer, malignant melanoma, and endometrial cancer.
|
12203792 |
2002 |
|
Glioblastoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Mutations of PTEN have been found in various human cancers, including glioblastoma, prostate, breast, lung, and melanoma.
|
12435856 |
2002 |
|
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
U87MG/PTEN glioblastoma cells are more sensitive than U87MG/PTEN null cells to death induced by etoposide, a chemotherapeutic agent that induces DNA damage.
|
11729185 |
2002 |
|
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The dominant-negative IGF-IRs also prevented growth of U87 PTEN-negative glioblastoma cells when injected into nude mice.
|
12057025 |
2002 |
|
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Chromosomal deletions of 10q and candidate genes such as PTEN and DMBT1 have been thoroughly investigated in glioblastomas but few data specifically address oligodendrogliomas.
|
12507139 |
2002 |
|
Glioblastoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
These results were also confirmed by expressions of Ad-wt-PTEN and Ad-G129E-PTEN in other glioblastoma cells lacking functional PTEN, U251MG, and U373MG.
|
12414663 |
2002 |
|
Glioblastoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
LOH on 9p and/or CDKN2A deletion occurred more often in glioblastomas (P < 0.001), LOH on 17p/TP53 mutations occurred more frequently in anaplastic astrocytomas (AAs; P = 0.112), and LOH on 10q/PTEN mutation frequency was similar in glioblastomas and AAs (P < 0.001).
|
12173338 |
2002 |
|
Glioblastoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Mutational inactivation of PTEN has been reported in various malignancies, including endometrial cancers, ovarian cancers, and glioblastomas.
|
11964046 |
2002 |
|
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that PTEN participates in the genesis of GBM, and might be further studied as a candidate therapeutic agent in other testing systems.
|
12370766 |
2002 |
|
Glioblastoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Although deletions or inactivating mutations of the tumor suppressor gene PTEN (phosphatase and tensin homolog deleted on chromosome 10) are involved in the development of a variety of tumors including glioblastoma, melanoma, prostate cancer, breast cancer, endometrial cancers etc., the role of PTEN expression in human primary hepatocellular carcinoma (HCC) has not yet been clarified.
|
12669234 |
2003 |
|
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Short postoperative survival for glioblastoma patients with a dysfunctional Rb1 pathway in combination with no wild-type PTEN.
|
14519639 |
2003 |
|
Glioblastoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Somatic PTEN mutations occur with a wide distribution of frequencies in sporadic primary tumors, with the highest frequencies in endometrial carcinomas and glioblastoma multiform.
|
12938083 |
2003 |